A higher incidence of chronic diseases worldwide and the demand for advanced medication adherence systems are fueling growth in this market, which has the potential to surpass $3.9 billion by 2021. A new study by BCC Research examines the industry’s prospects and technologies by disease applications and geographical regions.
With commercial applications in many fields, the total amino acid market in the United States is projected to approach $2.5 billion by 2022. Amino acids have important roles in food for human consumption, animal feed, cosmetics, medicines, biotechnology and some industrial applications. In dollar terms, the most important current applications are in animal feed and human food. The threeprimary categories of commercial amino acids in the United States—animal feeds, flavorants and specialty uses—comprise a market in excess of $1.9 billion. Accounting for 18% of global consumption, the U.S. market is forecast to expand at a compound annual growth rate of 4.8% from 2017 to 2022, according to a new study by BCC Research.
Researchers and healthcare professionals worldwide are exploring avenues in microRNA research and development. MicroRNAs are noncoding regions of the genome that help control where and when genes are activated. The burgeoning market of microRNA tools for research, diagnostics, and therapeutics has the potential to approach $1.4 billion by 2021. The rising incidences of life-threatening diseases and a growing population are among factors driving growth of this market. Companies are focusing on the advancement of superior technologies to provide higher-quality treatment and improved therapies for patients. Increased government spending and new partnerships will bolster growth in this innovative industry.
Conditions such as immunodeficiency and bleeding disorders are powerful growth factors of the blood plasma industry. In a recent analysis, BCC Research found that the rising demand for immunoglobulins (more commonly known as antibodies), an integral part of the immune response, is the main driver of the global market for blood plasma products. Product launches and improvements in existing technologies are expected to expand this market from approximately $16.8 billion in 2016 to $23.0 billion by 2021.